<p>BALB/c mice (n = 5/group) were immunized with 10<sup>3</sup> (squares), 10<sup>5</sup> (circles), or 10<sup>7</sup> (triangles) CFU of SCHU S4<i>ΔclpB</i> (open symbols) or FSC200<i>ΔclpB</i> (closed symbols). Immunized mice and naïve controls (inverted triangle) were challenged six weeks later IN with 105 CFU of SCHU S4. *, significantly better survival versus mice immunized with FSC200<i>ΔclpB</i>.</p
a<p>Survival, LD<sub>50</sub>, and mean time-to-death (MTD) were determined 21 days after infection ...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...
<p>BALB/c mice were immunized ID with 10<sup>5</sup> CFU of LVS (square; n = 12) or FSC200<i>ΔclpB</...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
a<p>Mice were immunized with either LVS or ΔFTL_0883 at the indicated dose and then challenged with ...
<p>Mice (n = 5) were vaccinated i.d. (A) or i.n. (B) with 10-fold serial dilutions of Schu S4 Δ<i>pu...
<p>Survival of mice vaccinated with the three vaccine candidates and control mice after IP challenge...
Groups of 10 Balb/c mice were immunized with Flg-HA2-2-4M2e, Flg-HA2-1-4M2e, or Flg-4M2e fusion prot...
<p>BALB/c mice (n = 5/group) were inoculated ID with 10<sup>7</sup> CFU of FSC200<i>ΔclpB</i> (circl...
<p>Mice were immunized i.n. with PBS (solid triangle), 1.5 x 10<sup>4</sup> CFU (solid circle), 1.5 ...
<p>Groups of mice were infected i.n. (A, B, and C) or i.d. (D, E, and F) with wild-type Schu S4 (50 ...
<p>Blue asterisk, significantly greater survival than control mice or mice immunized with LVS; green...
SW and C57BL/6 female mice were immunized i.n. with 1x103 CFU of attenuated Ft LVS sodB mutant. Mice...
<p>In A) BALB/c mice were challenged intradermally with 1000 CFU of SCHU S4 (square), Δ<i>FTT0609</i...
a<p>Survival, LD<sub>50</sub>, and mean time-to-death (MTD) were determined 21 days after infection ...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...
<p>BALB/c mice were immunized ID with 10<sup>5</sup> CFU of LVS (square; n = 12) or FSC200<i>ΔclpB</...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
a<p>Mice were immunized with either LVS or ΔFTL_0883 at the indicated dose and then challenged with ...
<p>Mice (n = 5) were vaccinated i.d. (A) or i.n. (B) with 10-fold serial dilutions of Schu S4 Δ<i>pu...
<p>Survival of mice vaccinated with the three vaccine candidates and control mice after IP challenge...
Groups of 10 Balb/c mice were immunized with Flg-HA2-2-4M2e, Flg-HA2-1-4M2e, or Flg-4M2e fusion prot...
<p>BALB/c mice (n = 5/group) were inoculated ID with 10<sup>7</sup> CFU of FSC200<i>ΔclpB</i> (circl...
<p>Mice were immunized i.n. with PBS (solid triangle), 1.5 x 10<sup>4</sup> CFU (solid circle), 1.5 ...
<p>Groups of mice were infected i.n. (A, B, and C) or i.d. (D, E, and F) with wild-type Schu S4 (50 ...
<p>Blue asterisk, significantly greater survival than control mice or mice immunized with LVS; green...
SW and C57BL/6 female mice were immunized i.n. with 1x103 CFU of attenuated Ft LVS sodB mutant. Mice...
<p>In A) BALB/c mice were challenged intradermally with 1000 CFU of SCHU S4 (square), Δ<i>FTT0609</i...
a<p>Survival, LD<sub>50</sub>, and mean time-to-death (MTD) were determined 21 days after infection ...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...